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ABSTRACT: Oxidative stress is involved in cell death in neurodegenerative diseases. Dietary polyphenols can exert health
beneﬁts, but their direct eﬀects on neuronal cells are debatable because most phenolics are metabolized and do not reach the
brain as they occur in the dietary sources. Herein, we evaluate the eﬀects of a panel of bioavailable polyphenols and derived
metabolites at physiologically relevant conditions against H2O2-induced apoptosis in human neuroblastoma SH-SY5Y cells.
Among the 19 metabolites tested, 3,4-dihydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid, gallic acid, ellagic acid, and
urolithins prevented neuronal apoptosis via attenuation of ROS levels, increased REDOX activity, and decreased oxidative stress-
induced apoptosis by preventing the caspase-3 activation via the mitochondrial apoptotic pathway in SH-SY5Y cells. This
suggests that dietary sources containing the polyphenol precursors of these molecules such as cocoa, berries, walnuts, and tea
could be potential functional foods to reduce oxidative stress associated with the onset and progress of neurodegenerative
diseases.
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■ INTRODUCTION
Oxidative stress is involved in neuronal cell death, which is one
of the leading causes of neurodegenerative diseases such as
Alzheimer’s disease, Parkison’s disease, or cerebral ischemia
reperfusion after stroke.1 Oxidative stress is characterized by the
imbalance between antioxidants and the accumulation of
reactive oxygen species (ROS) and reactive nitrogen species
that can be spontaneously generated, such as superoxide anion
and hydrogen peroxide, or made due to exogenous factors, such
as drug exposure or radiation.2 ROS generally are found in the
course of cell death, mainly by apoptosis caused by intracellular
microenvironmental changes, and in the brain, leading to
neurodegeneration and cognitive decline.3
There is much evidence showing that naturally occurring
antioxidants such as vitamins, minerals, and phenolic
compounds present in high amounts in fruits, vegetables, and
natural products scavenge the free radicals, and their intake acts
as an upstream preventive measure to neurodegeneration.4,5 In
fact, dietary polyphenols have been reported to display
potential neuroprotective eﬀects as antioxidants preventing
oxidation of proteins, lipid peroxidation, and generation of ROS
as well as anti-inﬂammatory and anti-apoptotic properties in
several in vitro models of toxicity and animal models of
neurological disorders.6,7 In this regard, previous studies have
indicated the neuroprotective eﬀect of red wine-, grape-,
pomegranate-, cocoa-, and tea-derived polyphenols as sources
of ﬂavan-3-ols, stilbenes such as resveratrol (RSV), and
ellagitannins (ETs) using animal models of neurodegenerative
diseases.8−11 However, polyphenols are poorly bioavailable and
cannot reach systemic tissues as they occur in the dietary
sources. On the contrary, they are extensively metabolized and
converted by colonic microbiota into other metabolic forms.6,12
Therefore, the actual metabolites responsible for the in vivo
neuroprotective eﬀects of polyphenols are not entirely known.
To date, only low concentrations of a few polyphenol-
derived metabolites have been detected in the brain of animals,
that is, gallic acid (GA), ellagic acid (EA) and its gut microbial
derived metabolites urolithins,13−15 resveratrol and its microbial
metabolites,16 and also anthocyanins.17,18 Nevertheless, many
derived metabolites have been detected in the human
bloodstream, so that they should be taken into account as
potential candidates to exert the neuroprotective eﬀects
attributed to the polyphenolic dietary precursors.19,20
Whereas dietary polyphenols such as ETs, procyanidins, and
stilbenes are poorly bioavailable, we hypothesize here that their
derived metabolites, which can target the brain, could protect
neuronal cells from oxidative stress-induced cell death. To
check this hypothesis, we aimed at determining the anti-
apoptotic and antioxidant eﬀects of a panel of 19 polyphenol-
derived metabolites (Figure 1), at physiologically relevant
concentrations, on H2O2-induced neurotoxicity in human
neuroblastoma SH-SY5Y cells.
■ MATERIALS AND METHODS
Materials and Reagents. Trypan blue, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), hydrogen
peroxide solution, gallic acid (GA), ellagic acid (EA), 3,4-
dihydroxyphenylpropionic acid (DHPPA), 3,4-dihydroxyphenylacetic
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acid (DHPAA), and trans-resveratrol (RSV) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). The microbial EA-derived
urolithins were chemically synthesized and puriﬁed by Villapharma
Research S.L. (Parque Tecnoloǵico de Fuente Alamo, Murcia, Spain).
Urolithin D (Uro-D) and urolithin C (Uro-C) were purchased from
Dalton Pharma Services (Toronto, Canada). RES-sulfate, RES-
glucuronide, and the microbial RES-derived metabolites dihydror-
esveratrol (DHR) and DHR-glucuronide were obtained as described
in Azorıń-Ortuño et al.16 Phosphate-buﬀered saline (PBS) was
obtained from Fisher Scientiﬁc (USA). Dimethyl sulfoxide (DMSO)
was obtained from Panreac (Barcelona, Spain). Milli-Q system
(Millipore Corp., USA) ultrapure water was used throughout the
study.
Cell Culture. The SH-SY5Y neuroblastoma cell line was purchased
from the European Collection of Authenticated Cell Cultures
(ECACC) (Salisbury, UK). Cells were cultured as recommended by
the ECACC in Ham’s F12:EMEM (EBSS) (1:1) + 2 mM glutamine +
1% nonessential amino acids + 15% fetal bovine serum (FBS). Cells
were incubated at 37 °C in a humidiﬁed atmosphere of 95% air/5%
CO2. Test compounds were solubilized in DMSO (<0.5% in the
culture medium) and were ﬁlter sterilized (0.2 μm) prior to addition
to the culture media. Control cells were also run in parallel and
subjected to the same changes in medium with 0.5% DMSO. Passages
from 22, after recultivation from −80 °C stocks, to 28 were used for all
of the experiments.
Cell Treatments and Viability. Cells (1.5 × 104 cells/well) were
seeded in 96-well plates and were incubated for 1 day to allow for
attachment and acclimatization. H2O2 was used to induce oxidative
stress. SH-SY5Y cells were treated with H2O2 at concentrations
ranging from 20 to 400 μM for 24 h, and 100 μM was ﬁnally selected
(showing 40−60% inhibition) to examine the neuroprotective eﬀects
of polyphenol-derived metabolites. To assess the dose-dependent
neuroprotective eﬀects of the phenolic compounds and derived
metabolites against H2O2-induced oxidative stress, cells were pre-
treated with each test molecule (1, 5, or 10 μM) for 6 h and then
exposed to 100 μM H2O2 for 24 h (i.e., pretreatment) or cells were
not pretreated with the molecules but incubated jointly with H2O2 for
24 h (1, 5, or 10 μM test molecule + 100 μM H2O2) (i.e.,
cotreatment).
After each assay, cell viability was measured using the MTT assay as
described elsewhere.21 The cytotoxic eﬀect was calculated as the
percentage of cell proliferation values with respect to the control cells
(0.5% DMSO; 100%). Data are presented as the mean ± SD of at least
ﬁve separate experiments.
Measurement of Reactive Oxygen Species. The measurement
of ROS was performed using the ROS-sensitive 2′,7′-dichlorodihydro-
ﬂuorescein diacetate (H2DCFDA) staining method (Sigma, St. Louis,
MO, USA). Following treatments, the medium was removed and
incubated with 25 μM H2DCFDA for 2 h at 37 °C in the dark.
H2DCFDA, a cell permeable nonﬂuorescent, is de-esteriﬁed intra-
cellularly and turns to the highly ﬂuorescent permeant molecule 2′,7′-
dichloroﬂuorescein (DCF) in the presence of intracellular ROS upon
oxidation. Fluorescence intensity was measured at an excitation
wavelength of 495 nm and an emission wavelength of 520 nm using a
multimode microplate reader (FLUOstar Omega, BMG Labtech,
Ortenberg, Germany).
Measurement of Mitochondrial Oxidation−Reduction
(REDOX) Activity. The analysis of REDOX activity was performed
using the ﬂuorogenic oxidation−reduction indicator resazurin (Life
Techonologies Inc., Rockville, MD, USA). After treatments, resazurin
dissolved in water at a ﬁnal concentration of 5 μM was added to the
wells, and the ﬂuorescence intensity was examined at an excitation of
530 nm and an emission of 590 nm. The plate was incubated for 2 h,
and then ﬂuorescence was measured using a microplate reader
described above.
Analysis of Apoptosis by Annexin V/PI Assay. The analyses of
apoptosis induction were performed in triplicate (n = 2 plates per
experiment) for each treatment and were carried out using the
Annexin V/propidium iodide (PI) detection kit (Molecular Probes,
Life Technologies Inc.) as speciﬁed by the manufacturer. Brieﬂy,
ﬂoating and adherent cells (0.5 × 106) were resuspended in 400 μL of
binding buﬀer and incubated in the dark with both Annexin V and PI
for 15 min. Then, a minimum of 25,000 cells per sample was analyzed
by ﬂow cytometry (Coulter, EPICS XL-MCL, Miami, FL, USA).
Staurosporine (Sigma) 5 μM was assayed as a standard inducer of
apoptosis. The percentage of living (negative in both Annexin V-FITC
and PI), early apoptotic (positive in Annexin V-FITC and negative in
PI), late apoptotic (positive in both Annexin V-FITC and PI), and
necrotic cells (positive only in PI) was calculated.
Evaluation of Caspase Activation by Flow Cytometry. The
activation of caspase-3, -8, and -9 was evaluated by ﬂow cytometry
using the carboxyﬂuorescein (FAM) FLICA apoptosis detection kits
FAM-DEVD-FMK, FAM-LETD-FMK and FAM-LEHD-FMK, re-
spectively (Immunochemistry Technologies LLC, Bloomington, MN,
USA).21
Experiments were carried out three times for each treatment (n = 2
plates per experiment) in FL1-A channel (Coulter, EPICS XL-MCL).
A minimum of 2 × 104 cells was analyzed for each sample.
Statistical Analysis. Data are presented as mean values ± SD.
Graphs of the experimental data were performed using Sigma Plot 13.0
(Systat Software, San Jose, CA, USA). Two-tailed unpaired Student’s t
test was used for statistical analysis of the data. A p value <0.05 was
considered signiﬁcant.
■ RESULTS
Bioavailable Phenolics and Derived Metabolites
Protect SH-SY5Y Cells from H2O2-Induced Cytotoxicity.
The compounds did not exert cytotoxic eﬀects when incubated
for 6−48 h using the highest concentration (10 μM) as cell
growth or viability (always >90%) was not signiﬁcantly aﬀected
(data not shown). H2O2 alone decreased SH-SY5Y cell viability
around 40−50% compared with the DMSO control (Figure 2).
Figure 1. Chemical structures of polyphenol-derived metabolites
evaluated in the study.
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Both the pretreatment and cotreatment experiments with GA,
EA, DHPPA, and DHPAA (10 μM) signiﬁcantly attenuated the
H2O2-induced cytotoxicity (p < 0.05) (Figure 2A) compared
with the H2O2 treatment alone. The pretreatment with
urolithins (10 μM) showed slight neuroprotective eﬀects,
although signiﬁcant (p < 0.05), except for Uro-B glucuronide,
whereas no eﬀects were observed with the cotreatment for any
urolithin (Figure 2B). No protective eﬀects were observed for
any compound at 1 or 5 μM (data not shown), except for
DHPPA, DHPAA, GA (cotreatment and pretreatment), and
EA (only pretreatment) (p < 0.05) at 5 μM (Figure 2C).
We next investigated the potential mechanisms involved in
the neuroprotective eﬀects, so that only the most eﬀective
compounds (DHPPA, DHPAA, GA, EA, and urolithin A (Uro-
A), a representative urolithin) were used for subsequent
experiments.
Eﬀects on H2O2-Induced Intracellular ROS Accumu-
lation and REDOX Activity. The eﬀects of the selected
metabolites (DHPPA, DHPAA, GA, EA, and Uro-A) on
intracellular ROS levels and REDOX activity are shown in
Tables 1 and 2, respectively. As cell viability was reduced by
50% in H2O2-treated cells, with the subsequent loss of
ﬂuorescence, we evaluated the intracellular ROS generation
and REDOX activity at shorter incubation time (2 h) to
conﬁrm the protective eﬀect of the metabolites on H2O2-
induced oxidative stress. We also evaluated the intracellular
ROS generation and REDOX activity of each metabolite alone,
without H2O2 treatment, after 6 h of incubation.
As shown in Table 1, H2O2 remarkably boosted the
intracellular ROS levels in SH-SY5Y cells, yielding DCF-
ﬂuorescence intensity around 4-fold higher (p < 0.05) than in
control cells. Both pretreatment and cotreatments with
DHPPA, DHPAA, GA, EA, and Uro-A led to a signiﬁcant
decrease in ROS levels compared to H2O2 treatment alone (p <
0.05), except for the cotreatment with Uro-A (Table 1).
With regard to REDOX activity, H2O2 treatment led to a
signiﬁcant decrease of REDOX activity (p < 0.05) compared to
control cells (Table 2), which was attenuated by both
pretreatment and cotreatment with DHPPA, DHPAA, GA,
and EA (p < 0.05), but not with Uro-A (Table 2). No
diﬀerences were observed in REDOX activity between control
cells and pretreatment with each metabolite alone for 6 h,
except in the case of Uro-A, in which a slight decrease (p <
0.05) was observed.
Bioavailable Phenolics and Derived Metabolites
Decrease H2O2-Induced Apoptosis. H2O2 treatment
signiﬁcantly increased the percentage of late apoptotic cells
(∼17%, p < 0.05) when compared to the control (Figure 3).
Consistent with the neuroprotective eﬀects observed in the
Figure 2. Eﬀect of polyphenol-derived metabolites (10 μM) (6 h
pretreatment and 24 h cotreatment with H2O2, 100 μM) on cell
viability (%) in SH-SY5Y cells (A, B). Eﬀect of DHPPA, DHPAA, GA,
and EA (5 and 1 μM) (pretreatment and cotreatment with H2O2) on
cell viability (%) in SH-SY5Y cells (C). Values (%) are expressed as
the mean ± SD (n = 5). (a) Signiﬁcant diﬀerence (p < 0.05) compared
to control cells. (b) Signiﬁcant diﬀerence (p < 0.05) compared to
H2O2 treatment alone.
Table 1. Eﬀect of Metabolite Pretreatment and Cotreatment
on ROS Generation in SH-SY5Y Cells
relative amount of intracellular ROSa (%)
treatment 0 h, no oxidative stress 2 h pretreatment 2 h cotreatment
control 100.0 ± 3.5 100.0 ± 7.8 100.0 ± 11.3
H2O2 415.5 ± 132.6a 386.7 ± 17.4s
Uro-A 77.7 ± 8.8a 393.4 ± 120.1ab 398.0 ± 14.0a
DHPPA 62.3 ± 13.5a 338.5 ± 133.8ab 289.0 ± 17.9ab
DHPAA 64.9 ± 17.3a 332.8 ± 144.8ab 338.9 ± 15.3ab
GA 105.2 ± 2.4 360.1 ± 137.6ab 332.5 ± 19.4ab
EA 109.3 ± 9.6 383.0 ± 135.9ab 357.6 ± 13.2ab
aValues (%) are expressed as the mean ± SD (n = 3). (a) Signiﬁcant
diﬀerence (p < 0.05) compared to control cells. (b) Signiﬁcant
diﬀerence (p < 0.05) compared to H2O2 treatment alone.
Table 2. Eﬀect of Metabolite Pretreatment and Cotreatment
with H2O2 on REDOX Activity in SH-SY5Y Cells
relative amount of REDOX activitya (%)
treatment 0 h, no oxidative stress 2 h pretreatment 2 h cotreatment
control 100.0 ± 6.1 100.0 ± 7.8 100.0 ± 9.1
H2O2 57.05 ± 8.4a 54.8 ± 5.9a
Uro-A 81.6 ± 9.8a 62.6 ± 7.0a 60.0 ± 7.2a
DHPPA 92.0 ± 6.7 69.0 ± 7.1ab 72.3 ± 8.3ab
DHPAA 90.3 ± 13.7 70.9 ± 12.3ab 71.1 ± 5.5ab
GA 91.0 ± 4.9 72.3 ± 5.1ab 82.0 ± 7.3ab
EA 92.4 ± 4.8 65.9 ± 8.0ab 72.1 ± 4.4ab
aValues (%) are expressed as the mean ± SD (n = 3). (a) Signiﬁcant
diﬀerence (p < 0.05) compared to control cells. (b) Signiﬁcant
diﬀerence (p < 0.05) compared to H2O2 treatment alone.
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MTT assay, pretreatment with DHPPA, DHPAA, GA, EA, or
Uro-A signiﬁcantly decreased the percentage of late apoptosis
(8−12%, p < 0.05) compared to H2O2 treatment, with no
signiﬁcant diﬀerences between each metabolite (Figure 3A). A
similar trend was observed after cotreatment with DHPPA,
DHPAA, GA, or EA, except in the case of Uro-A, for which the
cotreatment did not protect SH-SY5Y cells from apoptosis
(Figure 3B).
Prevention of H2O2-Induced Caspase Activation by
Bioavailable Phenolics and Derived Metabolites. Figure 4
shows the activation of caspase-3 and -9 (10−14%, p < 0.05),
but not caspase-8, after H2O2 treatment. Pretreatment with
each metabolite signiﬁcantly attenuated H2O2-induced activa-
tion of both caspases-3 and -9 (p < 0.05) (Figure 4A). The
cotreatment with each metabolite exerted a similar attenuation
in the activation of both caspases (p < 0.05), except for Uro-A
(Figure 4B). Notably, although no diﬀerences were found
between these metabolites, higher attenuations were observed
by DHPPA and DHPAA.
■ DISCUSSION
Epidemiological studies link the adherence to healthy diets such
as the Japanese and Mediterranean diets to a lower risk of
neurodegenerative diseases.20 Given the involvement of ROS in
neurodegenerative diseases, research has focused on the
potential beneﬁcial eﬀects of natural antioxidant compounds
due to their ability to inhibit ROS generation and protect
neuronal cells from oxidative damage or death.7 On this point, a
number of studies have highlighted the potential role of dietary
polyphenols in neurodegenerative disease prevention and
treatment, in which the attenuation of ROS generation,
apoptotic signal, or inﬂammatory response has been proposed
as a mechanism of action.19,22,23 However, clinical evidence
supporting the speciﬁc role of dietary polyphenols in the
prevention of neurodegenerative diseases is still very limited. In
this regard, better knowledge about the bioavailability, tissue
distribution, and metabolism of dietary polyphenols will
facilitate the identiﬁcation of the putative actors in the
Figure 3. Eﬀect of DHPPA, DHPAA, GA, EA, and Uro-A (10 μM) on
apoptosis induction (early and late apoptosis) in SH-SY5Y cells: 6 h of
pretreatment (A) and 24 h of cotreatment with H2O2 (B). Values (%)
are expressed as the mean ± SD (n = 5). (a) Signiﬁcant diﬀerence (p <
0.05) compared to control cells. (b) Signiﬁcant diﬀerence (p < 0.05)
compared to H2O2 treatment alone.
Figure 4. Eﬀect of DHPPA, DHPAA, GA, EA, and Uro-A (10 μM) on
caspase-3, -8, and -9 activation in SH-SY5Y cells: 6 h pretreatment (A)
and 24 h cotreatment with H2O2 (B). Values (%) are expressed as the
mean ± SD (n = 5). (a) Signiﬁcant diﬀerence (p < 0.05) compared to
control cells. (b) Signiﬁcant diﬀerence (p < 0.05) compared to H2O2
treatment alone.
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prevention of neurodegenerative diseases following polyphenol-
rich diets.20 However, to date, most studies have been
performed following exposure of cultured neuronal cells to
food extracts, complex polyphenols, or single compounds in
molecular forms and concentrations that do not occur in vivo.
This means that the in vivo potential neuroprotective eﬀect of
dietary polyphenols remains unclear. Indeed, the ability of
dietary phenolics or their derived metabolites produced in vivo
to prevent oxidative stress in the central nervous system will
depend on their bioavailability as well as their capacity to cross
the blood−brain barrier (BBB).19,24 Therefore, there is a need
to design improved in vitro studies that better reﬂect, at least
partially, the in vivo environment. For the above reasons, and
taking into account previous bioavailability human studies, we
assayed here some bioavailable phenolic compounds and their
phase II conjugates as well as microbial-derived metabolites,
which can reach the bloodstream and even pass through the
BBB.14
Our results revealed that among 19 diﬀerent metabolites
examined, the pretreatment and cotreatment of SH-SY5Y cells
with DHPPA, DHPAA, GA, or EA as well as the pretreatment
with urolithins exerted a potent protection against H2O2-
induced oxidative stress. It is well-known that H2O2-induced
oxidative stress markedly increases the intracellular ROS levels
and may induce apoptosis or necrosis by intracellular
microenvironmental changes.25,26 In our study we performed
the exogenous H2O2 treatment that has been widely used to
induce oxidative stress27 in the human neuroblastoma SH-SY5Y
cell line. Our data conﬁrmed both the increase of ROS levels
and apoptosis induction through the intrinsic pathway because
caspase-9 is activated, which ﬁnally leads to caspase-3
activation, without aﬀecting caspase-8 activation in H2O2-
treated SH-SY5Y human neuroblastoma cells. In general, these
metabolites reduced intracellular ROS levels, increased REDOX
activity, and decreased oxidative stress-induced apoptosis by
preventing caspase-3 activation via the mitochondrial apoptotic
pathway in SH-SY5Y cells. On the contrary, other studies have
reported the activation of both extrinsic and intrinsic apoptotic
pathways28,29 as well as the activation of caspase-3 only via
caspase-8 after higher treatments with H2O2 on SH-SY5Y
cells.30
To the best of our knowledge, this study represents the ﬁrst
attempt to identify the molecule(s) responsible for the
neuroprotective eﬀects of dietary phenolic compounds in a
more realistic approximation to the in vivo scenario.
Resveratrol (RSV) is a plant-derived polyphenol with
promising activity against neurodegenerative diseases.31,32
However, most studies aiming at identifying mechanisms
related to the potential neuroprotective activity of RSV did
not take into account its limited bioavailability, microbial
biotransformation into DHR, and subsequent phase-II
metabolism to yield diﬀerent conjugated metabolites, which
are more likely to interact with systemic tissues such as the
central nervous system.32 In fact, RSV and diﬀerent metabolites,
both microbial and phase II conjugates, have been detected in
the cerebrospinal ﬂuid (CSF) and brain of pigs after oral RSV
administration.16 In our study, unlike previous papers that
showed protection against H2O2-induced oxidative injury after
treatment with high RSV aglycone concentrations,33,34 we did
not observe signiﬁcant protection against oxidative stress-
induced damage using physiologically relevant RSV metabolites
and low concentrations. Remarkably, Turner et al.35 recently
described the occurrence of RSV and derived metabolites in the
CSF of patients with mild−moderate Alzheimer’s disease.
Despite the high RSV amount administered (from 0.5 to 2 g
daily for 1 year), no clinical eﬀects were observed in these
patients.35 Therefore, our in vitro results support that
physiologically relevant concentrations of RSV and its derived
metabolites do not seem to be useful in the prevention of
oxidative-triggered neurodegenerative processes.
With regard to EA and GA, both phenolics are well-known
antioxidant compounds with reported neuroprotective activity
in diﬀerent models of neurodegeneration, neurotoxicity, and
oxidative stress, although more studies are needed to verify
their real implication in the neuroprotective eﬀect.36,37 To the
best of our knowledge, the present study shows for the ﬁrst
time that EA exerted neuroprotective activity by preventing
H2O2-induced oxidative stress. A recent pharmacokinetic
human study has reported that EA bioavailability is not as
low as previously described and can reach low micromolar
levels in the bloodstream.38 EA has also been detected in the rat
brain after the consumption of EA.15 Therefore, EA could be a
putative actor in the neuroprotection associated with the intake
of certain plant foods.39 With regard to GA, it has also been
detected in the brain of a mouse model of Alzheimer’s disease
following grape seed extract administration13 and also in rats
after intravenous administration.14 Our data support previous
in vitro studies conducted in diﬀerent neuronal models that
have reported the neuroprotective eﬀect of GA by inhibiting
neuroinﬂammation in microglia and Neuro-2A cells40 and by
the attenuation of ROS generation in human astrocytoma U373
MG cells.41
The potential biological activity of the EA microbial-derived
metabolites urolithins is gaining increasing interest.42 However,
the evidence regarding their role in neuroprotection is still very
limited. To date, only an in vitro study has reported the
potential eﬀect of Uro-A and urolithin B (Uro-B) on the
survival of human neuroblastoma SK-N-MC cells subjected to
mild oxidative stress by incubation with 2,3-dimethoxy-1,4-
naphthoquinone (DMNQ).43 In addition, a recent study has
also shown that Uro-A, Uro-B, and their methylated conjugates
prevented the ﬁbrillation of β-amyloid proteins in vitro and
exerted a protective eﬀect post-induction of β-amyloid induced
neurotoxicity and paralysis in the nematode Caenorhabditis
elegans.44 Notably, urolithins are able to cross the BBB,
suggesting their possible role in the neuroprotective activity
following the intake of ET-rich foods.14 On this point, our
present study describes for the ﬁrst time the potential
neuroprotective activity of urolithins (Uro-A, -B, -C, and -D)
and their bloodstream-occurring glucuronide conjugates against
H2O2-induced cell injury. Our results showed that neither the
diﬀerential hydroxylation pattern of urolithins or the phase II
metabolism was critical for its neuroprotective eﬀect, showing
no diﬀerences among all of the urolithins, aglycones, and
glucuronide conjugates, except the lack of eﬀect for Uro-B.
Although our results suggest a lower neuroprotective activity of
urolithins against oxidative stress-induced cell death than their
parent compound EA, further studies are needed to identify the
real bioactive components responsible for the neuroprotective
eﬀects observed in preclinical studies after ET-rich food
intake.39
Finally, the strongest neuroprotective activity was observed
with the phenolic acids DHPPA and DHPAA. In agreement
with our results, the 30 min pretreatment of DHPPA acid and
DHPAA at similar doses exhibited a slight, but signiﬁcant,
protective eﬀect in human neuroblastoma SK-N-MC cells
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subjected to DMNQ-induced oxidative stress.43 These
phenolics are the primary microbial-derived phenolic acids
that can be found in the bloodstream (up to 10 μM)45 after the
ingestion of plant foods containing proanthocyanidins and
ﬂavan-3-ols such as cocoa, tea, and wine.46 Therefore, our data
suggest that these compounds could play an important role in
the neuroprotective actions associated with ﬂavanol-rich food
intake in human studies.47,48
In conclusion, our approach provides further evidence
regarding the neuroprotective activity of physiologically
relevant polyphenol-derived metabolites. Unlike previous
impressive in vitro eﬀects reported for polyphenols as they
occur in the dietary source, the activity exerted by the
circulating metabolites is much lower. Overall, our results
suggest that a diet rich in foods containing polyphenol
precursors of DHPPA, DHPAA, GA, and EA such as cocoa,
tea, strawberry, walnut, and pomegranate could contribute to
reduce oxidative stress in relation to the onset of neuro-
degenerative diseases. However, further studies are needed to
investigate the detailed molecular mechanisms underlying the
neuroprotective eﬀects of these polyphenol-derived metabo-
lites.
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DCF, 2′,7′-dichloroﬂuorescein; DHPAA, 3,4-dihydroxyphenyl-
acetic acid; DHPPA, 3,4-dihydroxyphenylpropionic acid; DHR,
dihydroresveratrol; DMNQ, 2,3-dimethoxy-1,4-naphthoqui-
none; DMSO, dimethyl sulfoxide; EA, ellagic acid; ECACC,
European Collection of Authenticated Cell Cultures; EMEM,
Eagle’s minimal essential medium; ETs, ellagitannins; FAM,
carboxyﬂuorescein; FBS, fetal bovine serum; GA, gallic acid;
glur, glucuronide; H2DCFDA, 2′,7′-dichlorodihydroﬂuorescein
diacetate; IsoUro-A, isourolithin A; MTT, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; PBS, phos-
phate-buﬀered saline; PI, propidium iodide; ROS, reactive
oxygen species; RSV, trans-resveratrol; SD, standard deviation;
sulf, sulfate; Uro-A, urolithin A; Uro-B, urolithin B; Uro-C,
urolithin C; Uro-D, urolithin D
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